Thera-SAbDab

GANITUMAB

>   Structural Summary
TherapeuticGanitumab
TargetIGF1R
Heavy ChainQVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARWTGRTDAFDIWGQGTMVTVSS
Light ChainDVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-III
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2010
INN Year Recommended2011
Companies InvolvedAmgen, Millennium, NantWorks, National Cancer Institute (USA), Novartis, Takeda, Takeda Oncology, UCLAs Jonsson Comprehensive Cancer Center
Conditions Approvedna
Conditions ActiveEwing's sarcoma, Solid tumours, Rhabdomyosarcoma
Conditions DiscontinuedBreast cancer, Colorectal cancer, Sarcoma, Small cell lung cancer, Non-small cell lung cancer, Pancreatic cancer, Prostate cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]